Search

Search Constraints

You searched for: Author/Creator Hagemeister, Frederick

Search Results

1. Four‐year follow‐up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL). (22nd May 2018)

2. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. Issue 1 (January 2016)

3. Long‐term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib. (2nd September 2018)

4. Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma. Issue 12 (3rd May 2018)

5. Ultra–low‐dose radiotherapy for definitive management of ocular adnexal B‐cell lymphoma. Issue 5 (19th March 2019)

6. Ultra–low‐dose radiotherapy for definitive management of ocular adnexal B‐cell lymphoma. Issue 6 (21st February 2018)

7. Ultra–low‐dose radiotherapy for definitive management of ocular adnexal B‐cell lymphoma. Issue 6 (3rd April 2017)